Table 3 Analysis of 24-month disease-free survival rate (DFS) and post-operative ctDNA clearance by TNM stage
Stage I-II | Stage III | |||
|---|---|---|---|---|
24-month DFS (%) | All patients | No ctDNA information | 96.1% (123/128) | 82.9% (29/35) |
Clinically high-risk patients | No ctDNA information | 94.0% (79/84) | 81.3% (26/32) | |
24-month DFS (%) | All patients | Pre-operative ctDNA(+) | 90.7% (39/43) | 77.8% (21/27) |
Pre-operative ctDNA(−) | 100.0% (82/82) | 100.0% (8/8) | ||
Clinically high-risk patients | Pre-operative ctDNA(+) | 89.5% (34/38) | 76.9% (20/26) | |
Pre-operative ctDNA(−) | 100.0% (43/43) | 100.0% (6/6) | ||
All patients | Post-operative ctDNA(+) | 25.0% (1/4) | 28.6% (2/7) | |
Post-operative ctDNA(−) | 100.0% (101/101) | 100.0% (25/25) | ||
Clinically high-risk patients | Post-operative ctDNA(+) | 25.5% (1/4) | 28.6% (2/7) | |
Post-operative ctDNA(−) | 100.0% (61/61) | 100.0% (23/25) | ||
Percentage of patients having post-operative ctDNA clearance by adjuvant therapy | Clearance (Pos → Neg) | 100.0% (4/4) | 63.6% (7/11) | |
No clearance (Pos → Pos or relapse) | 0.0% (0/0) | 36.4% (4/11) | ||
